NCT02744729View on ClinicalTrials.gov

99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Esophageal Cancer
Interventions
DRUG

99mTc-3PRGD2

For patients in suspicion of esophagus cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.

Trial Locations (1)

350005

Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

First Affiliated Hospital of Fujian Medical University

OTHER

NCT02744729 - 99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients | Biotech Hunter | Biotech Hunter